Kingsview Wealth Management’s Mustang Bio MBIO Stock Holding History

Kingsview Wealth Management’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-20	Closed	-$61K	–	553
2019 Q4	$61K	Buy	+20	New	+$45.8K	0.01%	454

Other funds holding MBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Kingsview Wealth Management's MBIO Position: Q1 2020 in Review

Kingsview Wealth Management sold out of Mustang Bio (MBIO) in Q1 2020, closing a stake of 20 shares — an estimated $61K sold.

Kingsview Wealth Management first reported a position in MBIO in Q4 2019 and held it in 1 quarter. The position peaked at $61K in Q4 2019. 64 funds tracked by Wall St. Rank hold MBIO as of Q1 2020.

Kingsview Wealth Management reported no remaining Mustang Bio position as of Q1 2020 after selling out during the quarter.
Kingsview Wealth Management sold 20 Mustang Bio shares in Q1 2020, an estimated $61K.
Kingsview Wealth Management first reported a position in Mustang Bio in Q4 2019 and held it in 1 quarter.
Kingsview Wealth Management's Mustang Bio position peaked at $61K in Q4 2019.
64 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2020.

Based on Kingsview Wealth Management's 13F filing for Q1 2020, filed 11 May 2020.